A share price of Humacyte Inc [HUMA] is currently trading at $3.51, up 8.33%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HUMA shares have gain 12.86% over the last week, with a monthly amount drifted -21.30%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 18, March 2024, Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024. In a post published today on Yahoo Finance, Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the fourth quarter and year ended December 31, 2023, on Friday, March 22, 2024. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.
From an analyst’s perspective:
Humacyte Inc [NASDAQ: HUMA] stock has seen the most recent analyst activity on December 11, 2023, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $6. Previously, Piper Sandler upgraded its rating to Neutral on August 14, 2023, and elevated its price target to $3.50. On June 22, 2023, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $6 on the stock. Piper Sandler downgraded its rating to a Underweight and decreased its price target to $4 on May 16, 2022. Cowen initiated its recommendation with a Outperform and recommended $17 as its price target on October 29, 2021. Oppenheimer started tracking with a Outperform rating for this stock on September 24, 2021, and assigned it a price target of $16. In a note dated September 22, 2021, BTIG Research initiated an Buy rating and provided a target price of $19 on this stock.
Humacyte Inc experienced fluctuations in its stock price throughout the past year between $1.96 and $5.60. Currently, Wall Street analysts expect the stock to reach $4.5 within the next 12 months. Humacyte Inc [NASDAQ: HUMA] shares were valued at $3.51 at the most recent close of the market. An investor can expect a potential return of 28.21% based on the average HUMA price forecast.
Analyzing the HUMA fundamentals
Trailing Twelve Months sales for Humacyte Inc [NASDAQ:HUMA] were 0.00M which represents -100.00% decline. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -1.31 and Total Capital is -0.71. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.53.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.32 points at the first support level, and at 3.12 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.66, and for the 2nd resistance point, it is at 3.80.
Humacyte Inc [HUMA] reported earnings per share of -$0.25 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.25/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.22 per share as compared to estimates of -$0.22 per share, a difference of $0 representing a surprise of 0.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Humacyte Inc [NASDAQ:HUMA] is 6.79. As well, the Quick Ratio is 6.79, while the Cash Ratio is 6.61.
Transactions by insiders
Recent insider trading involved Dougan Brady W, Director, that happened on Sep 14 ’23 when 2.0 million shares were sold. President, CEO and Director, Niklason Laura E completed a deal on Sep 14 ’23 to sell 2.0 million shares. Meanwhile, 10% Owner Ayabudge LLC sold 0.6 million shares on Aug 21 ’23.
